Connor, Clark & Lunn Investment Management (CC&L)’s Coherus Oncology, Inc. Common Stock CHRS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-88,022
| Closed | -$697K | – | 1266 |
|
|
2022
Q4 | $697K | Buy |
+88,022
| New | +$697K | ﹤0.01% | 797 |
|
|
2022
Q3 | – | Sell |
-48,389
| Closed | -$350K | – | 1124 |
|
|
2022
Q2 | $350K | Sell |
48,389
-15,402
| -24% | -$111K | ﹤0.01% | 841 |
|
|
2022
Q1 | $824K | Buy |
+63,791
| New | +$824K | ﹤0.01% | 697 |
|
|
2021
Q1 | – | Sell |
-14,211
| Closed | -$247K | – | 992 |
|
|
2020
Q4 | $247K | Sell |
14,211
-1,678
| -11% | -$29.2K | ﹤0.01% | 805 |
|
|
2020
Q3 | $291K | Sell |
15,889
-352
| -2% | -$6.45K | ﹤0.01% | 793 |
|
|
2020
Q2 | $290K | Buy |
+16,241
| New | +$290K | ﹤0.01% | 848 |
|